Reducing carbohydrate intake, increasing protein, cycling caloric intake, or implementing time-restricted eating windows can break through metabolic adaptation
Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications primarily prescribed for type 2 diabetes management and, in some formulations, for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
View Dr Rimas Geigas profile Dr Snieguole Geige Explore the clinics approach to responsible medical education and evidence interpretation
This attention to detail is for researchers in controlled lab settings
So, how effectively can we improve metabolic health using this exciting new nutraceutical GLP-1 agonist Eriomin
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al